News and

A New Publication Highlights the Use of cResponse in the Assessment of Response to Treatments for Pancreatic Cancer

Curesponse discusses with the Jerusalem Post its innovative cResponse™ test that helps tailor the optimal treatment for breast cancer patients.

Curesponse discuss with the Jerusalem Post its cResponse test that can predict which drugs will benefit individual cancer patients.

Curesponse Presents Positive Preliminary Clinical Results from a Multi-Center UK Study at AACR

Curesponse discusses its cancer prediction cResponse™ test with Ynet (in hebrew)

Yahoo finance logo - Curesponse announces coverage for cResponse Test with Clalit Health Services

Curesponse Announces Clalit Health Services, Largest Israeli HMO, to Provide Commercial Coverage for the cResponse™ test

Curesponse shows applicability with next generation immuno-oncology drugs

Curesponse to exhibit at ASCO, 2022

Curesponse to present at BIOMED Israel, 2022

Curesponse publishes new clinical study in Nature Cancer

Want to know more?

Contact Us